Summaries of newly published research, clinical trial updates, and compound news.
A new Journal of Analytical Toxicology study shows that even trace dermal exposure to trenbolone and metenolone can produce detectable urinary metabolites. The findings do not establish how common accidental transfer is, but they give anti-doping laboratories better evidence for interpreting positive tests and evaluating contamination claims.
In the phase 3 SYNCHRONIZE-1 trial, the investigational GLP-1/glucagon dual agonist survodutide produced significantly greater weight loss than placebo in adults with obesity without diabetes. The findings do not establish superiority over semaglutide or tirzepatide, but they provide important late-stage evidence on efficacy and gastrointestinal tolerability.
The FDA approved Wegovy HD (semaglutide 7.2mg) on March 19, 2026 — the highest weight loss yet recorded for a Wegovy injection. Here’s what the STEP UP trial data, side-effect trade-offs, and pricing actually mean.
Semaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits three. Here’s the actual biology behind why adding receptors keeps pushing GLP-1 drug efficacy higher — and where the ceiling might be.
The FDA approved Foundayo (orforglipron) on April 1, 2026 — the first oral small-molecule GLP-1 with no food or water restrictions. Here’s what the ATTAIN trial data, pricing, and National Priority Voucher fast-track actually mean.
A new Yale/PNAS study finds GLP-1 drugs recruit hunger-driving AgRP neurons rather than suppress them — overturning a long-held assumption and revealing a sex-specific mechanism that could reshape future obesity drug design.
A new research direction could eventually change how obesity medicines are designed: instead of repeatedly injecting a finished peptide or protein, mRNA-LNP systems may deliver genetic instructions directly to metabolic tissues. Recent peer-reviewed work describes adipose-targeted lipid nanoparticles carrying GLP-1/FGF21 mRNA, while a new Nature Reviews Endocrinology perspective frames the field as a potential route toward longer-lasting, programmable metabolic therapy. The science is promising but remains entirely preclinical for obesity, with major questions around delivery, repeat dosing, immune effects, manufacturing, and translation to humans.
TRIUMPH-4 didn’t just show record weight loss — it left more than 1 in 8 patients completely free of knee pain. Here’s what the osteoarthritis-specific trial data shows, separate from retatrutide’s weight-loss headline.
If you’re on compounded semaglutide or tirzepatide, the regulatory ground is shifting under you. Here’s a concrete checklist for what to actually verify and ask before your next refill.
Since November 2025, the FDA has sent over 50 warning letters to online peptide sellers in three coordinated waves. Here’s what the agency is actually targeting, using real letters as case studies.
